p.310 抽出テキスト

ただし,NSAIDs の鎮痛効果については1 週間程度で評価し,効果がなければ他のNSAIDs に変更せず,オピオイドに変更する。一定期間,オピオイドとNSAIDsを併用してもよい。

【引用文献】1) Alamdarsaravi M, Ghajar A, Noorbala AA, et al. Efficacy and safety of celecoxib monotherapy for mild to moderate depression in patients with colorectal cancer:a randomized double‒ blind, placebo controlled trial. Psychiatry Res 2017;255:59‒65 2) 内田正興,野口明彦,小川一誠.癌性疼痛に対するKetoprofen 坐剤の二重盲検比較試験による検討Indomethacin, placebo との比較.診療と新薬1982;19:795‒805 3) Stambaugh J, Drew J. A double‒blind parallel evaluation of the efficacy and safety of a single dose of ketoprofen in cancer pain. J Clin Pharmacol 1988;28(Suppl 1):S34‒9 4) Mohammadinejad P, Arya P, Esfandbod M, et al. Celecoxib versus diclofenac in mild to moderate depression management among breast cancer patients:a double‒blind, placebo‒ controlled, randomized trial. Ann Pharmacother 2015;49:953‒61 5) Rodríguez MJ, Contreras D, Gálvez R, et al. Double‒blind evaluation of short‒term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain 2003;104:103‒10 6) Pannuti F, Robustelli della Cuna G, Ventaffrida V, et al. A double‒blind evaluation of the analgesic efficacy and toxicity of oral ketorolac and diclofenac in cancer pain. The TD/10 recordati Protocol Study Group. Tumori 1999;85:96‒100 7) Yalçin S, GüllüIH, Tekuzman G, et al. A comparison of two nonsteroidal antiinflammatory drugs(diflunisal versus dipyrone)in the treatment of moderate to severe cancer pain:a randomized crossover study. Am J Clin Oncol 1998;21:185‒8 8) Toscani F, Piva L, Corli O, et al. Ketorolac versus diclofenac sodium in cancer pain. Arzneimittelforschung 1994;44:550‒4 9) Gallucci M, Toscani F, Mapelli A, et al. Nimesulide in the treatment of advanced cancer pain. Double‒blind comparison with naproxen. Arzneimittelforschung 1992;42:1028‒30 10) Ventafridda V, Toscani F, Tamburini M, et al. Sodium naproxen versus sodium diclofenac in cancer pain control. Arzneimittelforschung 1990;40:1132‒4 11) 古江尚,仁井谷久暢,栗原稔,他.LFP83 の癌性疼痛に対する有用性の検討 注射用ケトプロフェンとの二重盲検比較試験.臨と研1989;66:2014‒24 12) Levick S, Jacobs C, Loukas DF, et al. Naproxen sodium in treatment of bone pain due to metastatic cancer. Pain 1988;35:253‒8 13) Turnbull R, Hills LJ. Naproxen versus aspirin as analgesics in advanced malignant disease. J Palliat Care 1986;1:25‒8 14) Corli O, Cozzolino A, Scaricabarozzi I. Nimesulide and diclofenac in the control of cancer‒ related pain. Comparison between oral and rectal administration. Drugs 1993;46(Suppl 1): 152‒5 15) Ventafridda V, De Conno F, Panerai AE, et al. Non‒steroidal anti‒inflammatory drugs as the first step in cancer pain therapy:double‒blind, within‒patient study comparing nine drugs. J Int Med Res 1990;18:21‒9 16) Wool C, Prandoni P, Polistena P, et al. Ketorolac suppositories in the treatment of neoplastic pain:a randomized clinical trial versus diclofenac. Curr Ther Res 1991;49:854‒61 17) Martino G, Ventafridda V, Parini J, et al. A controlled study on the analgesic activity of indoprofen inpatients with cancer pain. Bonica JJ, Albe‒Fessard D, eds. Pharmacological Agents in Chronic Pain, Advances in Pain Research and Therapy. Vol. 1. New York, Raven Press, 1976:pp573‒8 18) Sacchetti G, Camera P, Rossi AP, et al. Injectable ketoprofen vs. acetylsalicylic acid for the relief of severe cancer pain:a double‒blind, crossover trial. Drug Intell Clin Pharm 1984;18: 403‒6 19) Saxena A, Andley M, Gnanasekaran N. Comparison of piroxicam and acetylsalicylic acid for pain in head and neck cancers:a double‒blind study. Palliat Med 1994;8:223‒9 20) Yousef AA, Alzeftawy AE. The efficacy of oral piroxicam fast‒dissolving tablets versus sublingual fentanyl in incident breakthrough pain due to bone metastases:a double‒blinded randomized study. Support Care Cancer 2019;27:2171‒7 21) Rodríguez M, Barutell C, Rull M, et al. Efficacy and tolerance of oral dipyrone versus oral III章推奨